Immuno-oncology diagnosis market seen growing at 10% CAGR through 2030

The immuno-oncology diagnosis market is projected to rise from $13.8 billion in 2025 to $15.15 billion in 2026, then reach $22.16 billion by 2030, according to The Business Research Company. Growth is being driven by higher cancer prevalence, wider use of biomarker testing, and expanding demand for personalized cancer therapies.

Why it matters: - Immuno-oncology diagnostics help identify biomarkers and immune responses that guide cancer treatment decisions. - The market’s growth points to rising demand for testing that supports personalized immunotherapies, companion diagnostics, and earlier cancer detection. - The expansion also reflects broader investment in oncology research, clinical trials, and precision medicine tools.

What happened: - The Business Research Company released its Immuno Oncology Diagnosis Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on September 21, 2026. - The report projects the market will grow from $13.8 billion in 2025 to $15.15 billion in 2026. - The report forecasts the market will reach $22.16 billion by 2030. - The report places the market on a 9.7% CAGR path from 2025 to 2026 and a 10.0% CAGR through 2030. - Download a free sample of the report. - View the full market report.

The details: - Immuno-oncology diagnosis focuses on cancer-related biomarkers and immune responses to understand how tumors interact with the immune system. - The approach helps diagnose cancers, characterize disease, and guide treatment decisions. - The report links near-term growth to rising global cancer prevalence, greater use of targeted therapies, expansion of hospital diagnostic labs, broader adoption of immunohistochemistry in oncology, and advances in biomarker discovery technologies. - Longer-term growth is tied to demand for personalized cancer immunotherapies, liquid biopsy and other non-invasive diagnostics, AI-driven diagnostic platforms, precision medicine, companion diagnostics, and more oncology research and clinical trials. - Emerging trends in the market include liquid biopsy-based assays for early cancer detection and monitoring. - Other trends include multiplex immune profiling to map tumor microenvironments, companion diagnostic kits for immunotherapy selection, high-sensitivity flow cytometry for immune cell analysis, and AI-powered digital pathology software for biomarker interpretation. - The report says the market analysis covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The company says its 2026 market reports include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables.

Between the lines: - The market thesis is straightforward: more cancer cases plus more precise testing usually translates into more demand for diagnostic tools that can sort patients into the right treatment paths. - The emphasis on liquid biopsy, companion diagnostics, and AI suggests the market is moving toward faster, less invasive, and more data-heavy workflows. - The regional split also signals a mature North American base and faster expansion opportunities in Asia-Pacific. - In February 2024, the World Health Organization projected more than 35 million new cancer cases by 2050, up 77% from about 20 million in 2022.

What's next: - The market is expected to continue growing through 2030 as cancer incidence rises and precision oncology expands. - Adoption of AI-based pathology, liquid biopsy, and immune profiling tools is likely to shape product development and competitive positioning. - Investment in oncology research and clinical trials should keep supporting demand for companion diagnostics and biomarker testing. - The Business Research Company provided contact details for expert inquiries, including Saumya Sahay and marketing@tbrc.info.

The bottom line: - Immuno-oncology diagnosis is moving from a specialized testing niche to a core part of precision cancer care, with double-digit growth expected through the end of the decade.